Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Philip Morris International Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Philip Morris International Inc. trades at $208.89 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 319.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Philip Morris International Inc. pays a 3.21% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.
| MRVI | PM | |
|---|---|---|
Market Cap | $972.90M | $310.62B |
Volume | 4,325,710 | 4,145,126 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $205.58 |
52-Week Low | $2.83 | $144.33 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $1.08B | $353.73B |
Dividend Yield | — | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Philip Morris International (PM) trades at $199.29, down 1.34% on the day, with strong earnings momentum after beating Q1 and Q2 2026 EPS estimates. The company shows robust fundamentals with 2025 revenue of $40.65B and net income margin of 25.56%, though valuation ratios appear elevated. Technical indicators show a bullish moving average trend but overbought RSI signals, with key support at $199. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now representing over 40% of revenue.
PM's outlook remains positive with analyst consensus price target of $212.17 (6.5% upside) and 68% buy ratings. Growth is driven by smoke-free product adoption and international expansion, but risks include regulatory pressures, high debt levels, and premium valuation. The stock offers dividend income with recent $1.60 payout, supporting total return potential for investors comfortable with tobacco sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
